Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Polus plans to start production at Chulbatkan after 2028

6/16/23 PLZL

Sberbank completely withdrew from the European market

6/16/23 SBER

Owners of Noventiq receipts can receive up to three shares of Softline JSC

6/16/23 SOFL

Qiwi began splitting the business under the previously submitted plan

6/16/23 QIWI

Shareholders of Rosseti Lenenergo approved dividends for 2022

6/16/23 LSNG

Sberbank will continue to allocate 50% of profits to dividends

6/16/23 SBER

Segezha Group invests ₽15 billion in the construction of a paper machine

6/16/23 SGZH

Magnit will open about 40 stores in Bashkiria by the end of the year

6/16/23 MGNT

Adobe reported for 6 months of fiscal year 2023

6/16/23 ADBE

Rosseti's investment program in next two years will amount to ₽1 trillion

6/16/23 FEES